OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk that it has entered into a commercial agreement with KSF Acquisition UK Limited (‘KSF). The agreement provides funding to assess the benefits of using Optibiotix’s SlimBiome(R) weight management product alongside KSF’s weight management dietary programme and provides KSF with an option to commercialise SlimBiome(R).
OptiBiotix’s SlimBiome(R) contains ingredients clinically proven to reduce weight formulated by world experts to act at different parts of the body in three different ways to affect appetite, metabolism, and energy harvest.
KSF’s established brand with its scientifically proven weight management programme uses meal replacement products to support weight loss.
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the signing of this commercial agreement with KSF, whose dietary programme is a trusted and well recognised global brand in weight management. This agreement brings together OptiBiotix’s novel science with KSF’s industry expertise, product range, and market reach to access a market estimated globally to be worth $622bn in 2015. OptiBiotix continues to make strong commercial progress across all it platforms consistent with its strategy of creating multiple product and partnering opportunities for large global markets with an unmet need.”
